Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: | Updated:
Scott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.
